Skip to content

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures: A Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02967172
Enrollment
100
Registered
2016-11-18
Start date
2016-10-31
Completion date
2018-09-21
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Ankle Fractures

Brief summary

The purpose of this study is to determine the efficacy and safety of a peri-articular multimodal injection for post-operative pain control following operative management of closed, rotational ankle fractures. Enrolled subjects will be randomized to either receive or not receive intra-operative injections in addition to standard opioid analgesic regimens. Patients will be treated with standard of care surgical techniques by the treating orthopaedic surgeon for the patient's specific fracture pattern. The patients randomized into the injection cohort will receive a 25cc intra-operative injection with 200 mg ropivacaine, 0.6 mg epinephrine, 5 mg and morphine into the local superficial and deep peri-incisional tissues while under general anesthesia. Total post-operative opioid consumption expressed in morphine equivalent dose will be recorded, including IV and oral opioids. Time in hours from operation conclusion to discharge and discharge disposition (to where the patient is discharged) will also be recorded. Post-operative pain scores will be assessed and recorded in the immediate post-operative period and every 4 hours subsequently until the patient is discharged. Medication related side effects will be monitored. The investigators hypothesize that the injection cohort will have reduced pain scores, lower narcotic requirements, shorter length of stay, and be more likely to discharge to home following surgery.

Detailed description

Periarticular fractures (bone breaks extending into the joint surface) treated by orthopaedic surgeons are associated with significant pain in the post-operative period, often requiring high doses of opioid analgesics. In recent years, the high risk of misuse, abuse, and death associated with prescription opioid use has become increasingly evident. Although physicians are being advised to avoid administration of opioid prescriptions, alternative pain management options are limited. Currently, there is a need to investigate different pain management models in order to provide safe and effective pain relief during the post-operative period. The investigators aim to evaluate the effectiveness of peri-incisional multimodal injections as an alternative post-operative pain control method in orthopaedic trauma patients with operative ankle fractures. Approximately 200 patients will be randomized to either receive or not receive intra-operative injections in addition to standard opioid analgesic regimens. Post-operative pain management outcomes will be assessed and compared between the 2 study groups to determine effectiveness of the injections. The proposed study will build upon related work to advance post-operative pain control regimens in orthopaedic surgery. Goals include the reduction of unnecessary patient suffering, reliance on opioids, and length of stay, while improving patient experience. These aims will be accomplished through the expansion of currently used multimodal periarticular injections from populations undergoing elective surgery to orthopaedic trauma patients with rotational ankle fractures. The study design is a prospective, double-blinded, randomized controlled trial. Patients included in the study will be randomly assigned to one of two treatment groups: intra-operative multimodal periarticular injection or control (no injection). The peri-incisional injection will consist of ropivacaine, epinephrine, and morphine. All pharmacologic agents in the anesthetic cocktail are FDA approved and have been previously used in combination during other types of orthopaedic surgeries. All patients included in the study will receive standard post-operative opioid analgesic regimens, administered 'per needed', regardless of their assigned treatment group per study protocol. ≥ 40 patients will be randomly assigned to each group. The patients enrolled in the investigation as well as health care professionals performing post-operative assessments and collecting data will be blinded to treatment allocation. The feasibility of multimodal peri-incisional injections is supported by their current efficacy in populations undergoing elective orthopedic surgeries. These injections may be equally effective at reducing pain compared to regional anesthesia with continuous infusions, and single-shot nerve blocks. The investigators hypothesize that the injection cohort will have reduced pain scores, lower narcotic requirements, shorter length of stay, and be more likely to discharge to home following surgery.

Interventions

DRUGRopivacaine
DRUGEpinephrine
DRUGMorphine

Sponsors

University of Iowa
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* All consenting patients 18 years of age and older with operative, closed, rotational ankle fractures treated with internal fixation.

Exclusion criteria

* Patients with any of the following: * Allergy or medical contraindication to any of the study medications * Pregnant women * Diagnosed dementia * Preexisting opioid or illicit drug dependency * Major neuromuscular deficit * Severe systemic disorder (heart failure, respiratory failure, kidney failure, liver failure, or a clotting disorder) * Major head trauma * Concomitant distracting injury * Other surgical intervention in the study period (1 week) * Revision operations * Insists to receive peripheral nerve blocks for surgical anesthesia * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Change in Post-operative Visual Analog Pain Scores (VAS)Immediately following surgery, then every 4 hours following surgery for 48 hours post-surgery.The primary outcome was VAS pain over the first 48 hours postoperatively. Patients reported pain with use of a 100-mm VAS, with 0-mm being no pain and 100-mm being the most extreme pain imaginable. A higher score indicates worse pain. Scores were reported as mean values at 24 hours post-surgery and 48 hours post-surgery.

Secondary

MeasureTime frameDescription
Opioid Use in First 24 Hours Post-surgeryAt 24 hours post-surgery & during the total time of inpatient stay to dischageTotal opioid consumption expressed in morphine equivalent dose will be recorded, including IV and oral opioids, in the first 24 hours post-surgery.
Post-operative Length of StayFrom immediately following surgery to 90 days after.Number of days in the hospital following surgery
Patients Returning Home Following SurgeryFollowing hospital discharge from surgeryNumber of patients returning to their home following discharge, vs. going to a rehabilitation or skilled nursing facility

Other

MeasureTime frameDescription
Medication-related Side EffectsFrom immediately following surgery to 7 days after.Patients will be monitored by nursing personnel for medication side effects related to ropivacaine toxicity including blurred vision, hearing problems, transient peripheral paralysis, dizziness, convulsion, uncontrolled muscle contraction, hypotension, bradycardia, and new onset arrhythmia.

Countries

United States

Participant flow

Participants by arm

ArmCount
Peri-incisional Injection
A single, 25 cc multimodal analgesic cocktail will be injected following completion of ankle fracture fixation/instrumentation while the patient remains under general anesthesia and prior to skin closure. The injection will be administered as such: * 20 mL injected into the peri-incisional soft tissues in a circumferential fashion * 5mL injected into the ankle joint This cocktail includes 200 mg of 0.8% ropivacaine, 0.6 mg of epinephrine, 5 mg of morphine sulfate, and sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection. Interventions: Drug: Ropivacaine Drug: Epinephrine Drug: Morphine Drug: 0.9% sodium chloride solution Following surgery, patients in the treatment and non-treatment groups will both be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled per needed. Ropivacaine Epinephrine Morphine 0.9% sodium chloride solution
49
Control
Ankle fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
51
Total100

Baseline characteristics

CharacteristicTotalControlPeri-incisional Injection
Age44.6 years
STANDARD_DEVIATION 17.6
43.7 years
STANDARD_DEVIATION 17.6
45.4 years
STANDARD_DEVIATION 17.6
Age, Customized
Age range
40 years41 years40 years
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
60 Participants30 Participants30 Participants
Sex: Female, Male
Male
40 Participants21 Participants19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 490 / 51
other
Total, other adverse events
0 / 490 / 51
serious
Total, serious adverse events
0 / 490 / 51

Outcome results

Primary

Change in Post-operative Visual Analog Pain Scores (VAS)

The primary outcome was VAS pain over the first 48 hours postoperatively. Patients reported pain with use of a 100-mm VAS, with 0-mm being no pain and 100-mm being the most extreme pain imaginable. A higher score indicates worse pain. Scores were reported as mean values at 24 hours post-surgery and 48 hours post-surgery.

Time frame: Immediately following surgery, then every 4 hours following surgery for 48 hours post-surgery.

ArmMeasureGroupValue (MEAN)Dispersion
Peri-incisional InjectionChange in Post-operative Visual Analog Pain Scores (VAS)Mean VAS score 48hr post-op41 0 to 100 score on a scaleStandard Deviation 3
Peri-incisional InjectionChange in Post-operative Visual Analog Pain Scores (VAS)Mean VAS score 24hr post-op42 0 to 100 score on a scaleStandard Deviation 3
ControlChange in Post-operative Visual Analog Pain Scores (VAS)Mean VAS score 24hr post-op52 0 to 100 score on a scaleStandard Deviation 3
ControlChange in Post-operative Visual Analog Pain Scores (VAS)Mean VAS score 48hr post-op50 0 to 100 score on a scaleStandard Deviation 3
Secondary

Opioid Use in First 24 Hours Post-surgery

Total opioid consumption expressed in morphine equivalent dose will be recorded, including IV and oral opioids, in the first 24 hours post-surgery.

Time frame: At 24 hours post-surgery & during the total time of inpatient stay to dischage

ArmMeasureGroupValue (MEDIAN)
Peri-incisional InjectionOpioid Use in First 24 Hours Post-surgeryTotal inpatient opioid use29.0 Milligrams
Peri-incisional InjectionOpioid Use in First 24 Hours Post-surgeryOpioid use 24hr post-surgery25.5 Milligrams
ControlOpioid Use in First 24 Hours Post-surgeryTotal inpatient opioid use32.7 Milligrams
ControlOpioid Use in First 24 Hours Post-surgeryOpioid use 24hr post-surgery28.3 Milligrams
Secondary

Patients Returning Home Following Surgery

Number of patients returning to their home following discharge, vs. going to a rehabilitation or skilled nursing facility

Time frame: Following hospital discharge from surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Peri-incisional InjectionPatients Returning Home Following Surgery49 Participants
ControlPatients Returning Home Following Surgery46 Participants
Secondary

Post-operative Length of Stay

Number of days in the hospital following surgery

Time frame: From immediately following surgery to 90 days after.

ArmMeasureValue (MEDIAN)
Peri-incisional InjectionPost-operative Length of Stay22.3 Hours
ControlPost-operative Length of Stay22.5 Hours
Other Pre-specified

Medication-related Side Effects

Patients will be monitored by nursing personnel for medication side effects related to ropivacaine toxicity including blurred vision, hearing problems, transient peripheral paralysis, dizziness, convulsion, uncontrolled muscle contraction, hypotension, bradycardia, and new onset arrhythmia.

Time frame: From immediately following surgery to 7 days after.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026